Potential Application of Vaporized Drugs via Nasal Inhalers to Prevent Mortality and Central Nervous System Damage Caused by Primary Amoebic Meningoencephalitis Due to Naegleria fowleri

Ruqaiyyah Siddiqui, Siddiqui R, Abouleish MY, Mohamed Yehia Abouleish, Mustafa Khamis, Khamis M, Taleb Ibrahim, Ibrahim T, Khan NA
ACS pharmacology & translational science · 2021 · vol. 4(3) , pp. 1249–1252 · doi:10.1021/acsptsci.1c00086 · PMID:34151216 · PMC8205233
Other OA: closed
📄 Open PDF View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-10-03 ⓘ

This paper proposes using nasal inhalers with anti-Naegleria fowleri drugs or combinations including dexamethasone as a practical treatment for primary amoebic meningoencephalitis to prevent mortality and central nervous system damage.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Here, it is proposed that nasal inhalers with specific anti-Naegleria fowleri drugs or a combination of anti-N. fowleri compounds combined with steroids such as dexamethasone could provide a practical solution for treating primary amoebic meningoencephalitis.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-11T09:27:45.537177+00:00
pubmed
last seen: 2026-10-08T21:31:21.846955+00:00